全文获取类型
收费全文 | 1003篇 |
免费 | 103篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 33篇 |
妇产科学 | 3篇 |
基础医学 | 138篇 |
口腔科学 | 10篇 |
临床医学 | 178篇 |
内科学 | 336篇 |
皮肤病学 | 13篇 |
神经病学 | 32篇 |
特种医学 | 83篇 |
外科学 | 94篇 |
综合类 | 16篇 |
预防医学 | 82篇 |
眼科学 | 13篇 |
药学 | 47篇 |
2篇 | |
肿瘤学 | 30篇 |
出版年
2023年 | 5篇 |
2020年 | 16篇 |
2019年 | 15篇 |
2018年 | 15篇 |
2017年 | 8篇 |
2016年 | 11篇 |
2015年 | 14篇 |
2014年 | 19篇 |
2013年 | 32篇 |
2012年 | 34篇 |
2011年 | 21篇 |
2010年 | 28篇 |
2009年 | 32篇 |
2008年 | 43篇 |
2007年 | 39篇 |
2006年 | 44篇 |
2005年 | 39篇 |
2004年 | 53篇 |
2003年 | 20篇 |
2002年 | 39篇 |
2001年 | 34篇 |
2000年 | 39篇 |
1999年 | 48篇 |
1998年 | 36篇 |
1997年 | 27篇 |
1996年 | 24篇 |
1995年 | 26篇 |
1994年 | 26篇 |
1993年 | 18篇 |
1992年 | 31篇 |
1991年 | 20篇 |
1990年 | 28篇 |
1989年 | 30篇 |
1988年 | 19篇 |
1987年 | 18篇 |
1986年 | 20篇 |
1985年 | 16篇 |
1984年 | 16篇 |
1983年 | 14篇 |
1982年 | 6篇 |
1980年 | 10篇 |
1979年 | 16篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 11篇 |
1974年 | 5篇 |
1973年 | 4篇 |
1972年 | 7篇 |
1971年 | 3篇 |
排序方式: 共有1110条查询结果,搜索用时 15 毫秒
991.
Despite the longstanding interest and large number of publications on biomarkers in lupus, there are no validated and widely
accepted biomarkers of systemic lupus erythematosus to date. To achieve the ultimate goal, to have a biomarker as a surrogate
endpoint in clinical studies, candidate biomarkers have to first be validated in a statistically rigorous way. However, to
qualify as a surrogate endpoint, even validated biomarkers have to go through a process that demonstrates that they accurately
reflect a clinically important outcome. These goals can only be achieved in large multicenter, properly conducted studies.
We reviewed the difficulties involved in developing validated biomarkers for systemic lupus erythematosus and summarized the
available data on the most promising biomarker candidates of disease susceptibility and disease activity. We also report on
the current status of a multicenter initiative to concentrate efforts of biomarker development. 相似文献
992.
This paper summarizes the current status of water fluoridation in the United States and discusses the strategic plan developed by the Division of Oral Health (DOH), Centers for Disease Control and Prevention (CDC) to meet the Healthy People 2000 fluoridation objective. This objective proposes to: "Increase to a least 75 percent the proportion of people served by community water systems providing optimal levels of fluoride (baseline: 62% in 1989)." The CDC strategic plan defines the nature of the problem with attainment of this objective, sets CDC priorities, and establishes six major components for future action: (1) assessment, evaluation and surveillance; (2) consultation; (3) state and regional efforts; (4) professional education and involvement; (5) public education; and (6) quality assurance. Actions in each of the components of the plan to help in the attainment of priorities are detailed. Finally, the broader picture of the federal role in a national fluoride plan is discussed. 相似文献
993.
Summary E-selectin endothelial leucocyte adhesion molecule-1 is expressed on endothelial cells in distinct inflammatory skin diseases. E-selectin mediates the adhesion between activated endothelium and different inflammatory cells. To evaluate soluble E-selectin as a marker of disease activity in patients with atopic dermatitis and psoriasis, the concentration of soluble E-selectin, determined by ELISA, was studied in sera of patients before and after treatment and compared with normal non-atopic controls. The disease severity was established using clinical scoring systems. Levels of soluble E-selectin were significantly elevated in sera of patients with atopic dermatitis and psoriasis (as compared with controls). Clinical improvement, after treatment, in patients with atopic dermatitis, but not in psoriasis, was associated with a significant decrease in serum levels of soluble E-selectin. There was a significant correlation of soluble E-selectin and disease activity in patients with atopic dermatitis. These data indicate that soluble E-selectin is another parameter to evaluate the inflammatory response in atopic dermatitis and psoriasis. Determination of soluble E-selectin may be a useful measure of disease activity in atopic dermatitis. 相似文献
994.
Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions 总被引:13,自引:0,他引:13
下载免费PDF全文
![点击此处可从《The Journal of clinical investigation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Grammer AC Slota R Fischer R Gur H Girschick H Yarboro C Illei GG Lipsky PE 《The Journal of clinical investigation》2003,112(10):1506-1520
To determine the role of CD154-CD40 interactions in the B cell overactivity exhibited by patients with active systemic lupus erythematosus (SLE), CD19+ peripheral B cells were examined before and after treatment with humanized anti-CD154 mAb (BG9588, 5c8). Before treatment, SLE patients manifested activated B cells that expressed CD154, CD69, CD38, CD5, and CD27. Cells expressing CD38, CD5, or CD27 disappeared from the periphery during treatment with anti-CD154 mAb, and cells expressing CD69 and CD154 disappeared from the periphery during the post-treatment period. Before treatment, active-SLE patients had circulating CD38 (bright) Ig-secreting cells that were not found in normal individuals. Disappearance of this plasma cell subset during treatment was associated with decreases in anti-double-stranded DNA (anti-dsDNA) Ab levels, proteinuria, and SLE disease activity index. Consistent with this finding, peripheral B cells cultured in vitro spontaneously proliferated and secreted Ig in a manner that was inhibited by anti-CD154 mAb. Finally, the CD38(+/++)IgD(+), CD38(+++), and CD38(+)IgD(-) B cell subsets present in the peripheral blood also disappeared following treatment with humanized anti-CD154. Together, these results indicate that patients with active lupus nephritis exhibit abnormalities in the peripheral B cell compartment that are consistent with intensive germinal center activity, are driven via CD154-CD40 interactions, and may reflect or contribute to the propensity of these patients to produce autoantibodies. 相似文献
995.
996.
997.
998.
999.
Atherosclerotic risk factor reduction in peripheral arterial diseasea: results of a national physician survey
下载免费PDF全文
![点击此处可从《Journal of general internal medicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
McDermott MM Hahn EA Greenland P Cella D Ockene JK Brogan D Pearce WH Hirsch AT Hanley K Odom L Khan S Criqui MH Lipsky MS Hudgens S 《Journal of general internal medicine》2002,17(12):895-904
OBJECTIVE: Individuals with peripheral arterial disease (PAD) have a 3- to 6-fold increased risk of coronary heart disease and stroke compared to those without PAD. We documented physician-reported practice behavior, knowledge, and attitudes regarding atherosclerotic risk factor reduction in patients with PAD. DESIGN: National physician survey. PATIENTS/PARTICIPANTS: General internists (N = 406), family practitioners (N = 435), cardiologists (N = 473), and vascular surgeons (N = 264) randomly identified using the American Medical Association's physician database. MEASUREMENTS AND MAIN RESULTS: Physicians were randomized to 1 of 3 questionnaires describing a) a 55- to 65-year-old patient with PAD; b) a 55- to 65-year-old patient with coronary artery disease (CAD), or c) a 55- to 65-year-old patient without clinically evident atherosclerosis (no disease). A mailed questionnaire was used to compare physician behavior, knowledge, and attitude regarding risk factor reduction for each patient. Rates of prescribed antiplatelet therapy were significantly lower for the patient with PAD than for the patient with CAD. Average low-density lipoprotein levels at which physicians "almost always" initiated lipid-lowering drugs were 121.6 +/- 23.5 mg/dL, 136.3 +/- 28.9 mg/dL, and 149.7 +/- 24.4 mg/dL for the CAD, PAD, and no-disease patients, respectively (P <.001). Physicians stated that antiplatelet therapy (P <.001) and cholesterol-lowering therapy (P <.001) were extremely important significantly more often for the CAD than for the PAD patient. Perceived importance of risk factor interventions was highly correlated with practice behavior. Compared to other specialties, cardiologists had lowest thresholds, whereas vascular surgeons had the highest thresholds for initiating cholesterol-lowering interventions for the patient with PAD. Cardiologists were significantly more likely to report "almost always" prescribing antiplatelet therapy for the patient with PAD than were all other physicians. CONCLUSIONS: Deficiencies in physician knowledge and attitudes contribute to lower rates of atherosclerotic risk factor reduction for patients with PAD. Reversing these deficiencies may reduce the high rates of cardiovascular morbidity and mortality associated with PAD. 相似文献
1000.
Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study 总被引:4,自引:1,他引:3
W. J. Sandborn W. J. Tremaine J. A. Leighton G. M. Lawson B. J. Zins R. F. Compton D. C. Mays J. J. Lipsky K. P. Batts K. P. Offord R. D. Hurt & J. green 《Alimentary pharmacology & therapeutics》1997,11(4):663-671
Background: Ulcerative colitis is predominantly a disease of non-smokers, and transdermal nicotine is therapeutic but often results in side-effects. Administration of nicotine as a liquid rectal enema results in less systemic nicotine absorption. Aim: To determine the safety and clinical response of nicotine tartrate liquid enemas for active left-side ulcerative colitis in a pilot study. Methods: Ten non-smoking patients with mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy were treated in an open protocol with nightly nicotine tartrate liquid enemas at a dose of 3 mg nicotine base for 1 week then 6 mg for 3 weeks. Clinical assessments were determined at baseline and 4 weeks by endoscopy, physician assessment and a patient diary of daily symptoms. Peak and trough serum nicotine and trough plasma cotinine were determined by gas chromatography/mass spectrometry and high performance liquid chromatography, respectively. Results: After 4 weeks of treatment, 5/7 patients (71%) showed clinical and sigmoidoscopic improvement (per protocol analysis). The other three patients discontinued therapy within 7 days because of inability to retain the liquid enemas. No patients showed histologic improvement. Six of the patients who completed the 4-week study had peak and trough serum nicotine concentration determined, only 1 of 6 patients had a detectable peak nicotine concentration (value 2.3 ng/mL), and all six patients had undetectable trough nicotine concentrations. The mean trough plasma cotinine concentration was 13 ± 10 ng/mL. Transient and mild adverse events occurred in 4/10 patients (nausea, lightheadedness, tremor, sleep disturbance). Given the low or undetectable serum nicotine concentrations, these adverse events are not likely to be related to the nicotine enemas. Conclusions: Nicotine tartrate liquid enemas administrated at a dose of 3 mg nicotine base/day for 1 week and then 6 mg/day for 3 weeks are safe and appear to result in clinical improvement in some patients with mildly to moderately active, left-sided ulcerative colitis unresponsive to first-line therapy. Placebo-controlled trials are warranted to confirm these preliminary findings. 相似文献